内镜下经鼻蝶入路手术治疗泌乳素腺瘤患者:适应证与结局
该回顾性分析纳入2010年8月至2019年7月在同一多学科团队接受内镜下经鼻蝶入路切除的60例连续泌乳素腺瘤患者,最常见手术指征为患者意愿(26.6%)、多巴胺激动剂不耐受(25%)和DA失败(18.3%肿瘤缩小不足、15%持续高泌乳素血症、11.7%两者兼有),全切除率83%,92%患者住院1天,全部患者早期缓解率71%。作者认为在高容量垂体中心,内镜下经鼻蝶切除是泌乳素腺瘤治疗的可行选择,术后并发症少。
要点
- 手术指征以患者意愿(26.6%)、DA不耐受(25%)和DA失败(18.3%缩小不足、15%持续高泌乳素血症、11.7%两者兼有)为主。
- 全切除率83%,92%患者住院1天,全部患者早期缓解率71%,微腺瘤91%、大腺瘤56%。
- 仅3例复发,随访时间分别为4.3年、3.3年和1.6年。
核心结论
- 在高容量垂体中心,内镜下经鼻蝶切除是泌乳素腺瘤治疗的可行选择,术后并发症少。
研究设计与样本
- 回顾性分析2010年8月至2019年7月在同一多学科团队随访下接受内镜下经鼻蝶入路切除的60例连续泌乳素腺瘤患者。
主要发现
- 女性占手术病例73%,大腺瘤占60%。
- 最常见主要手术指征为患者意愿(26.6%),其次为DA不耐受(25%)和DA失败(18.3%肿瘤缩小不足、15%持续高泌乳素血症、11.7%两者兼有)。
- 全切除率83%,92%患者住院时间为1天。
- 全部患者早期缓解(术后第1天停用DA后泌乳素正常)率为71%,微腺瘤为91%,大腺瘤为56%,Knosp 0-2级大腺瘤为65%,以治愈为目的手术的大腺瘤为75%。
- 仅3例复发,随访时间分别为4.3年、3.3年和1.6年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clinical paradigms and consensus recommend dopamine agonists (DAs) as the primary treatment for prolactinomas. However, medically treated patients also encounter challenges such as DA resistance, intolerable side effects, and recurrence of hyperprolactinemia after DA withdrawal. Technical advances in transsphenoidal resection, with an endoscopic endonasal approach, have led to improved visualization of tumor, decreased postoperative morbidity, and shortened length of stay. We examined the indications and outcomes in patients with prolactinomas who underwent surgical resection at our center. METHODS: A retrospective analysis was performed of 60 consecutive patients with prolactinomas who underwent endoscopic endonasal transsphenoidal resection between August 2010 and July 2019 and were followed by the same multidisciplinary team. RESULTS: Women comprised 73% of surgical cases, and 60% of the tumors were macroadenomas. The most common primary surgical indication was patient preference (26.6%) followed by DA intolerance (25%) and DA failure (18.3% inadequate shrinkage, 15% persistent hyperprolactinemia, 11.7% both). Gross total resection was noted in 83% and length of stay was 1 day in 92% of patients. Early remission (postoperative day 1 normalization of prolactin off DA therapy) was seen in 71% of all patients, 91% of microadenomas, 56% of macroadenomas, 65% of Knosp grade 0-2 macroadenomas, and 75% of macroadenomas operated on with expectation of a cure. Only 3 patients had recurrence, at 4.3, 3.3, and 1.6 years of follow-up, respectively. CONCLUSIONS: Endoscopic endonasal resection is a viable option for management of patients with prolactinomas in the setting of a high-volume pituitary center, with minimal postoperative complications.
引用
- Force BK, Staggers K, Sebastian S, et al. Endoscopic Endonasal Transsphenoidal Surgery for Patients with Prolactinomas: Indications and Outcomes. World Neurosurg. 2022. PMID: 36270592. doi:10.1016/j.wneu.2022.10.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。